Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations

Abstract The human epidermal growth factor receptor 2 (HER2) alterations are significant genetic alterations in non-small cell lung cancer (NSCLC), encompassing mutations, amplifications, and protein overexpression. Despite the substantial progress of anti-HER2 targeted therapies in breast and gastr...

Full description

Bibliographic Details

Published in:	Journal of Translational Medicine
Main Authors:	Jiang Liu, Jianhua Liu, Jianhe Yu, Qun Ren, Yin Cai, Dadong Chen, Chuanjun Song
Format:	Article
Language:	English
Published:	BMC 2025-05-01
Subjects:	Human epidermal growth factor receptor 2 HER2 Non-small cell lung cancer Antibody drug conjugates T-DM1 T-DXd
Online Access:	https://doi.org/10.1186/s12967-025-06589-x